Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
September 06, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million...
Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
August 16, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
Dr. Davarpanah will lead Cidara’s oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 03, 2023 16:08 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics designed to help improve the standard of care for...
Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
July 31, 2023 16:30 ET
|
Cidara Therapeutics, Inc.
Cidara’s U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™ EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO, July 31, 2023 (GLOBE...
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
July 20, 2023 17:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Added to Russell Microcap® Index
June 26, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
June 22, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
June 20, 2023 09:55 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
June 13, 2023 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 16:37 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of...